Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 21

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 21
---
 preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent appropriate, this description will include, where applicable:

| • |     | the title and stated value; |

| • |     | the number of shares offered, the liquidation preference per share and the purchase price; |

| • |     | the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; |

| • |     | whether dividends will be cumulative or non-cumulative and, if 
 cumulative, the date from which dividends will accumulate;     |

| • |     | the procedures for any auction and remarketing, if any; |

| • |     | the provisions for a sinking fund, if any; |

| • |     | the provisions for redemption, if applicable; |

| • |     | any listing of the preferred stock on any securities exchange or market; |

| • |     | whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price 
 (or how it will be calculated) and conversion period;                                                           |

| • |     | voting rights, if any, of the preferred stock; |

| • |     | a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; |

| • |     | the identity of any depositaries, execution or paying agents, transfer agents, registrars or other agents; |

| • |     | the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, 
 dissolution or winding up of the affairs of the Company; and                                                   |

| • |     | any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity                 
 with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company. |

The preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights. 16

DESCRIPTION OF OUR WARRANTS We may issue warrants to purchase our common stock, preferred stock or debt securities in one or more series together with other securities or separately, as described in each applicable prospectus supplement and subject to applicable law. Below is a description of certain general terms and provisions of the warrants that we may offer.